Tisagenlecleucel
B-Cell CLL
National Cancer Institute (NCI)Cell therapyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the B-Cell CLL cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
Tisagenlecleucel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →